These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36804177)
1. In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease. Cox A; Tung M; Li H; Hallows KR; Chung EJ SLAS Technol; 2023 Aug; 28(4):223-229. PubMed ID: 36804177 [TBL] [Abstract][Full Text] [Related]
2. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Wüthrich RP; Kistler AD; Serra AL Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452 [TBL] [Abstract][Full Text] [Related]
3. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis. Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708 [TBL] [Abstract][Full Text] [Related]
9. Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Zafar I; Ravichandran K; Belibi FA; Doctor RB; Edelstein CL Kidney Int; 2010 Oct; 78(8):754-61. PubMed ID: 20686448 [TBL] [Abstract][Full Text] [Related]
10. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058 [TBL] [Abstract][Full Text] [Related]
11. Use of mammalian target of rapamycin inhibitors in patient with autosomal dominant polycystic kidney disease: an updated meta-analysis. Lin CH; Chao CT; Wu MY; Lo WC; Lin TC; Wu MS Int Urol Nephrol; 2019 Nov; 51(11):2015-2025. PubMed ID: 31578673 [TBL] [Abstract][Full Text] [Related]
12. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease model. Zhu P; Sieben CJ; Xu X; Harris PC; Lin X Hum Mol Genet; 2017 Jan; 26(1):158-172. PubMed ID: 28007903 [TBL] [Abstract][Full Text] [Related]
13. Investigation of Basolateral Targeting Micelles for Drug Delivery Applications in Polycystic Kidney Disease. Huang Y; Osouli A; Pham J; Mancino V; O'Grady C; Khan T; Chaudhuri B; Pastor-Soler NM; Hallows KR; Chung EJ Biomacromolecules; 2024 May; 25(5):2749-2761. PubMed ID: 38652072 [TBL] [Abstract][Full Text] [Related]
14. Rapamycin-mediated suppression of renal cyst expansion in del34 Pkd1-/- mutant mouse embryos: an investigation of the feasibility of renal cyst prevention in the foetus. Stayner C; Shields J; Slobbe L; Shillingford JM; Weimbs T; Eccles MR Nephrology (Carlton); 2012 Nov; 17(8):739-47. PubMed ID: 22725947 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level? Canaud G; Knebelmann B; Harris PC; Vrtovsnik F; Correas JM; Pallet N; Heyer CM; Letavernier E; Bienaimé F; Thervet E; Martinez F; Terzi F; Legendre C Am J Transplant; 2010 Jul; 10(7):1701-6. PubMed ID: 20642692 [TBL] [Abstract][Full Text] [Related]
16. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines. Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233 [TBL] [Abstract][Full Text] [Related]
17. Recent Advances of mTOR Inhibitors Use in Autosomal Dominant Polycystic Kidney Disease: Is the Road Still Open? Kou P; Wei S; Xiong F Curr Med Chem; 2019; 26(16):2962-2973. PubMed ID: 29600752 [TBL] [Abstract][Full Text] [Related]
18. Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. He J; Zhou H; Meng J; Zhang S; Li X; Wang S; Shao G; Jin W; Geng X; Zhu S; Yang B Pharmacol Res; 2020 May; 155():104751. PubMed ID: 32151678 [TBL] [Abstract][Full Text] [Related]
19. A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Kipp KR; Rezaei M; Lin L; Dewey EC; Weimbs T Am J Physiol Renal Physiol; 2016 Apr; 310(8):F726-F731. PubMed ID: 26764208 [TBL] [Abstract][Full Text] [Related]
20. Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Mekahli D; Decuypere JP; Sammels E; Welkenhuyzen K; Schoeber J; Audrezet MP; Corvelyn A; Dechênes G; Ong AC; Wilmer MJ; van den Heuvel L; Bultynck G; Parys JB; Missiaen L; Levtchenko E; De Smedt H Pflugers Arch; 2014 Aug; 466(8):1591-604. PubMed ID: 24193408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]